The Grohar Lab focuses on developing and clinically translating novel small molecule therapies for the treatment of pediatric solid tumors. A number of pediatric solid tumors have clear oncogenic driver mutations that are considered by many to be "undruggable." The lab has primarily focused on Ewing sarcoma and the development of therapies that target the EWS-FLI1 transcription factor. More recently, we have extended our focus to other solid tumors with the goal of better understanding therapeutic vulnerabilities at the interface of transcription and epigenetics. We have a number of compounds in various stages of clinical development including a cli